Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.

Blood - 15 Aug 2001

Linenberger M L, Hong T, Flowers D, Sievers E L, Gooley T A, Bennett J M, Berger M S, Leopold L H, Appelbaum F R, Bernstein I D

Abstract excerpt

Expression of multidrug resistance (MDR) features by acute myeloid leukemia (AML) cells predicts a poor response to many treatments. The MDR phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML. Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD33 antibody linked to calicheamicin, is effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to Carbocyanines
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporine

Share to Drug Synergism

Share to Immunotoxins

Share to Leukemia, Myeloid

Share to Remission Induction

Source

Identifiers

PMID: 11493443
DOI: 10.1182/blood.v98.4.988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.PMID 11493443Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

Classical multidrug resistance in acute myeloid leukaemia.Semantic proximity Read ↗

A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.Semantic proximity Read ↗

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).Semantic proximity Read ↗

[Multidrug resistance in acute leukemia].Semantic proximity Read ↗

Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Semantic proximity Read ↗

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 TrialSemantic proximity Read ↗

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublinesSemantic proximity Read ↗

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read ↗

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.